We are continuously striving to improve the quality of treatment to patients suffering from non-melanoma skin cancer, the world’s most common tumours of the skin. Our goal is to offer an effective, personalised and non-invasive treatment, independent of tumour size, severity and localization. Providing a fast, painless, single treatment with no side effects and aesthetic results. Meeting patient needs and bringing back quality of life.

Rhenium-SCT®
Epidermal Radioisotope Therapy
for the treatment of basal and squamous cell carcinomas

Bringing back Quality of Life.
single-session  painless  aesthetic
**Rhenium-188** is a radioisotope specially produced for medical applications. Its beta-radiation has ideal properties for the local treatment of skin cancers.

With a maximum of 2.1 MeV, the beta-radiation of **Rhenium-188** has a penetration depth of ~ 2 – 3 mm in human tissue (92% of its dose is delivered within the first 3 mm). The energy of the beta radiation is localised and deposited exactly in the tumour tissue, leaving the surrounding healthy tissue unharmed.

The **Rhenium-SCT®** (Skin Cancer Therapy) is therefore ideal for an effective, personalized therapy of non-melanoma skin cancers (basal and squamous cell carcinomas, incl. Bowen’s disease), independent of the size, localization or severity of the tumor.

The medical effect of **Rhenium-SCT®** is based on the local direct cytotoxic effect of the beta particles, which triggers a local apoptosis and immune reaction. OncoBeta® provides all of the necessary equipment and required hardware (treatment unit and applicator) as well as various accessories needed for the treatment.

When used properly and the **Rhenium-SCT®** is applied according to its intended use together with its treatment unit and applicator, there is no relevant systemic radiation exposure of the patient (0.05 – 0.1 mSv) or of the treatment team (0.05 – 0.1 mSv for the patient and in average 0.7 µSv per treatment for the operators). The **Rhenium-SCT®** is CE mark approved as a Medical Device of OncoBeta® GmbH.
Step 1:
The Skin Cancer Specialist marks the area needed to treat by the Rhenium-SCT® and prepares the treatment area if necessary.

Referral and admission to the nuclear medicine professional. Determination of the size of the area needed to treat.

Application of the special transparent protective foil.

Step 2:
Measurement of initial radioactivity of the Rhenium-188-Compound in the Carpoule.

Application of Rhenium-188-Compound on the area to be treated using the specially designed Applicator.

Measurement of remaining radioactivity in the Carpoule.

Calculation of treatment time.

Step 3:
Removal of the protective foil with dry Rhenium-188-Compound.

Disposal of radioactive waste in the waste disposal unit

Control of potential radioactive contamination on patient.

Discharge from the Nuclear Medicine Professional.

Healing process and growth of new skin tissue after 30 – 180 days.
Almost all patients undergoing a Rhenium-SCT® obtained a complete remission of the treated lesions.

For the majority of the patients (89%) the Rhenium-SCT® is a single-session treatment. Depending on the depth of the lesion, several applications may be required.
1. **Patient**
- Patient notices superficial changes in his/her skin
- Patient schedules an appointment with a dermatologist

2. **Dermatologist**
- Dermatologic evaluation
- Dermatologist diagnoses BCC*/SCC** incl. Bowen's disease. If required a skin biopsy is taken
- Referral of patient to a skin cancer treatment center/clinic.

3. **Skin Cancer Specialist**
- Scheduling of consultations
- Discussion of treatment alternatives

4. **Nuclear Medicine Physician**
- If decision is made for the Rhenium-SCT® treatment

5. **Dermatologist**
- Appointment for aftercare/follow-up
- Documentation of healing process

6. **Patient**
- Lesion treated (remission)
- Patient schedules regular check-ups with dermatologist

* BCC = basal cell carcinoma
** SCC = squamous cell carcinoma
Rhenium-SCT®
Epidermal Radioisotope Therapy

- Dermatologic evaluation
- Dermatologist diagnoses BCC*/SCC** incl. Bowen’s disease. If required a skin biopsy is taken
- Referral of patient to a skin cancer treatment center/clinic.
- Lesion treated (remission)
- Patient schedules regular check-ups with dermatologist

If decision is made for the Rhenium-SCT® treatment
**Rhenium-SCT®**
Epidermal Radioisotope Therapy

- non-invasive
- painless, no need for anesthesia
- single-session in most cases
- short duration of treatment
- personalised
- improved quality of life
- certified medical device
- aesthetic

---

**OncoBeta® GmbH**
Lichtenbergstraße 8
85748 Garching bei München
GERMANY
Tel: +49 (89) 5484224-0
Fax: +49 (89) 5484224-9
info@oncobeta.com
www.oncobeta.com

Version: C
Date: 25.04.2018